(Q79854404)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

main subject

phase II clinical trial

1 reference

1 reference

Jean-Marc Ferrero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Emmanuel Chamorey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Stephane Oudard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sabine Dides

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gerard Lesbats

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gerard Cavaglione

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Pierre Nouyrigat

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Cyril Foa

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Regis Kaphan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

738-745

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Advances in prostate cancer chemotherapy: a new era begins.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22070

7 January 2021

Identifiers

DOI

10.1002/CNCR.22070

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826591%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference